Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer


Creative Commons License

Turan N., BENEKLİ M., DANE F., Unal O. U., KARA H. V., Koca D., ...More

THORACIC CANCER, vol.5, no.5, pp.398-404, 2014 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 5 Issue: 5
  • Publication Date: 2014
  • Doi Number: 10.1111/1759-7714.12107
  • Journal Name: THORACIC CANCER
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.398-404
  • Keywords: Adjuvant chemotherapy, bevacizumab, colorectal cancer, pulmonary metastasectomy, III COLON-CANCER, RANDOMIZED CONTROLLED-TRIAL, LUNG METASTASECTOMY, PHASE-III, PROGNOSTIC-FACTORS, K-RAS, BOLUS FLUOROURACIL, MUTATION STATUS, STAGE-II, OXALIPLATIN
  • Dokuz Eylül University Affiliated: Yes

Abstract

Introduction: We investigated the impact of modern chemotherapy regimens and bevacizumab following pulmonary metastasectomy (PM) from metastatic colorectal cancer (CRC).